Pruritogenic Molecules in the Skin of Patients with Dermatomyositis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 May 30

PMID 37250649

Authors

Anett Vincze

Erika Herczeg-Lisztes

Katalin Szabo

Tibor Gabor Beldi

Melinda Nagy-Vincze

Agnes Por

Jozsef Varga

Katalin Danko

Tamas Biro

Balazs Istvan Toth

Zoltan Griger

Affiliations

Soon will be listed here.

Abstract

Introduction: Pruritus is a common excruciating symptom in systemic autoimmune diseases such as dermatomyositis (DM) but the pathogenesis is not fully understood. We intended to investigate the targeted expression analysis of candidate molecules involved in the development of pruritus in lesional vs. non-lesional skin samples of patients affected with active DM. We looked for correlations between the investigated pruriceptive signaling molecules, disease activity, and itching sensation of DM patients.

Methods: Interleukins (IL-33 and IL-6), tumor necrosis factor α (TNF-α), peroxisome proliferator-activated receptor γ (PPAR-γ), and ion channels belonging to the transient receptor potential (TRP) family were analyzed. The expression of TNF-α, PPAR-γ, IL-33, IL-6, and TRP channels in lesional DM skin was evaluated by RT-qPCR and immunohistochemistry and was compared with non-lesional DM skin samples. Pruritus, disease activity, and damage of DM were evaluated by the 5-D itch scale and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), respectively. Statistical analysis was performed with IBM SPSS 28 software.

Results: A total of 17 active DM patients participated in the study. We could show that the itching score was positively correlated with the CDASI activity score (Kendall's tau-b = 0.571; = 0.003). TNF-α gene expression was significantly higher in lesional DM skin than in non-lesional DM skin ( = 0.009) and differed in the subgroups of patients with different itch intensities ( = 0.038). The mRNA expression of lesional IL-6 correlated positively with 5-D itch and CDASI activity score (Kendall's tau-b = 0.585; = 0.008 and 0.45; = 0.013, respectively). TRPV4 expressions were positively correlated with CDASI damage score (Kendall's tau-b = 0.626; < 0.001), but the mRNA expressions of the TRP family, PPAR-γ, IL-6, and IL-33 were not different in lesional and non-lesional samples. Immunohistochemistry analysis did not find significant alterations in the expressions of TNF-α, PPAR-γ, IL-6, and IL-33 in lesional and non-lesional regions.

Discussion: Our results argue that cutaneous disease activity, TNF-α, and IL-6 might play a central role in DM-associated itch, while TRPV4 plays a central role in tissue regeneration.

References

Hengstman G, De Bleecker J, Feist E, Vissing J, Denton C, Manoussakis M . Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008; 59(3-4):159-63. DOI: 10.1159/000114036. View

Sepmeyer J, Greer J, Koyama T, Zic J . Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006; 56(4):584-7. DOI: 10.1016/j.jaad.2006.10.033. View

Solomon A, Spain R, Kruer M, Bourdette D . Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011; 17(12):1472-87. DOI: 10.1177/1352458511412996. View

Bilgic H, Ytterberg S, Amin S, McNallan K, Wilson J, Koeuth T . Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009; 60(11):3436-46. DOI: 10.1002/art.24936. View

Lundberg I, Brengman J, Engel A . Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995; 63(1):9-16. DOI: 10.1016/0165-5728(95)00122-0. View

Oddis C, Rockette H, Zhu L, Koontz D, Lacomis D, Venturupalli S . Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis. ACR Open Rheumatol. 2022; 4(11):983-990. PMC: 9661830. DOI: 10.1002/acr2.11493. View

Ostadhadi S, Nikoui V, Haj-Mirzaian A, Kordjazy N, Dehpour A . The role of PPAR-gamma receptor in pruritus. Eur J Pharmacol. 2015; 762:322-5. DOI: 10.1016/j.ejphar.2015.06.009. View

Kamperman R, van der Kooi A, de Visser M, Aronica E, Raaphorst J . Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. Int J Mol Sci. 2022; 23(8). PMC: 9030619. DOI: 10.3390/ijms23084301. View

Elman S, Hynan L, Gabriel V, Mayo M . The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2009; 162(3):587-93. PMC: 2875190. DOI: 10.1111/j.1365-2133.2009.09586.x. View

10.

Kahremany S, Hofmann L, Gruzman A, Cohen G . Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. Int J Mol Sci. 2020; 21(14). PMC: 7402353. DOI: 10.3390/ijms21144883. View

11.

Bohan A, Peter J . Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7):344-7. DOI: 10.1056/NEJM197502132920706. View

12.

Kimmel M, Alscher D, Dunst R, Braun N, Machleidt C, Kiefer T . The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2005; 21(3):749-55. DOI: 10.1093/ndt/gfi204. View

13.

Rider L, Werth V, Huber A, Alexanderson H, Rao A, Ruperto N . Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S118-57. PMC: 3748930. DOI: 10.1002/acr.20532. View

14.

Chen Y, Fang Q, Wang Z, Zhang J, MacLeod A, Hall R . Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch. J Biol Chem. 2016; 291(19):10252-62. PMC: 4858974. DOI: 10.1074/jbc.M116.716464. View

15.

Yosipovitch G, Berger T, Fassett M . Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2019; 34(2):239-250. PMC: 7027518. DOI: 10.1111/jdv.15973. View

16.

Jiang Y, Armstrong D, Albrecht U, Atkins C, Noebels J, Eichele G . Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998; 21(4):799-811. DOI: 10.1016/s0896-6273(00)80596-6. View

17.

Oaklander A . Neuropathic itch. Semin Cutan Med Surg. 2011; 30(2):87-92. PMC: 3139924. DOI: 10.1016/j.sder.2011.04.006. View

18.

Miao X, Huang Y, Liu T, Guo R, Wang B, Wang X . TNF-α/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms. Neurosci Bull. 2017; 34(1):42-53. PMC: 5799114. DOI: 10.1007/s12264-017-0124-3. View

19.

Boyd A . Thiazolidinediones in dermatology. Int J Dermatol. 2007; 46(6):557-63. DOI: 10.1111/j.1365-4632.2007.03273.x. View

20.

Friedmann P, Cooper H, Healy E . Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol. 2005; 85(3):194-202. DOI: 10.1080/00015550510030104. View